Overview
Background
A/ Professor Simone M Goldinger is a clinician-researcher in dermatology with a subspecialty focus on skin cancer and digital health. Her work sits at the intersection of clinical dermatology, artificial intelligence, and longitudinal imaging, with a particular emphasis on non-melanoma skin cancer detection and surveillance. Her current research develops and validates equitable, data-driven approaches to skin cancer diagnosis, drawing on large-scale longitudinal datasets to improve accuracy, address algorithmic bias, and support real-world clinical implementation. A central goal is ensuring these AI-powered tools are effective across diverse patient populations and translatable into everyday clinical practice.
Earlier in her career, A/Prof Goldinger specialised in dermato-oncology, focusing on metastatic melanoma and the cutaneous toxicities associated with immune checkpoint inhibitors and targeted therapies. This background in advanced disease management provides a strong translational foundation for her current work, connecting insights from late-stage oncology to earlier detection, risk stratification, and long-term monitoring. Her research bridges clinical medicine, data science, and health equity — with the aim of improving outcomes for patients with skin cancer in Australia and beyond.
Availability
- Associate Professor Simone M Goldinger is:
- Available for supervision
Qualifications
- Bachelor (Honours) of Medicine, University of Zurich
- Masters (Research) of Medicine and Surgery and Medical Science, University of Zurich
- Doctoral (Research), University of Zurich
- Professional Doctorate, University of Zurich
- Fellow, Australasian College of Dermatologists, Australasian College of Dermatologists
Research impacts
Skin cancer is the most common cancer in Australia, and early detection can save lives. A/Prof Goldinger's research is working to make skin cancer diagnosis smarter, faster, and fairer — developing AI tools that can assist clinicians in spotting cancers earlier and monitoring high-risk patients more effectively over time. A key focus is equity: ensuring that AI diagnostic systems work well for all patients, regardless of skin tone or background. By identifying and correcting for bias in these tools before they reach the clinic, this research helps reduce the risk that AI makes existing health disparities worse. Her earlier work on the skin side effects of cancer treatments — including immunotherapy and targeted therapies — has contributed to better recognition and management of these complications, helping patients stay on life-saving treatments for longer. Together, this research aims to improve outcomes for skin cancer patients across Australia, support clinicians with better decision-making tools, and ensure that advances in digital health benefit everyone equitably.
Works
Search Professor Simone M Goldinger’s works on UQ eSpace
2014
Conference Publication
Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitis
Bjasch, D., Maggio, E. Marquez, Fitsche, A., Moch, H., Goldinger, S. M., Dummer, R. and Mihic-Probst, D. (2014). Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitis. NEW YORK: SPRINGER.
2014
Journal Article
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Moutouh-de Parseval, L., Dummer, R. and Goldinger, S. M. (2014). Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology, 25 (7), 1437-1441. doi: 10.1093/annonc/mdu169
2014
Journal Article
To B-(RAF) or Not to Be
Dummer, Reinhard, Goldinger, Simone M., Widmer, Daniel, Dreier, Jil and Levesque, Mitchell P. (2014). To B-(RAF) or Not to Be. Journal of Investigative Dermatology, 134 (5), 1200-1201. doi: 10.1038/jid.2014.62
2014
Conference Publication
Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanoma
Schilling, B., Sondermann, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J. C., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmar, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanoma. 41st Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF), Cologne Germany, Mar 13-15, 2014. HOBOKEN: WILEY.
2014
Journal Article
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma
Schilling, B., Sondermann, W., Zhao, F., Griewank, K. G., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kahler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25 (3), 747-753. doi: 10.1093/annonc/mdt587
2014
Journal Article
Vemurafenib in patients with <i>BRAF<SUP>V600</SUP></i> mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
Dummer, Reinhard, Goldinger, Simone M., Turtschi, Christian P., Eggmann, Nina B., Michielin, Olivier, Mitchell, Lada, Veronese, Luisa, Hilfiker, Paul Rene, Felderer, Lea and Rinderknecht, Jeannine D. (2014). Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer, 50 (3), 611-621. doi: 10.1016/j.ejca.2013.11.002
2014
Journal Article
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Van Allen, Eliezer M., Wagle, Nikhil, Sucker, Antje, Treacy, Daniel J., Johannessen, Cory M., Goetz, Eva M., Place, Chelsea S., Taylor-Weiner, Amaro, Whittaker, Steven, Kryukov, Gregory V., Hodis, Eran, Rosenberg, Mara, McKenna, Aaron, Cibulskis, Kristian, Farlow, Deborah, Zimmer, Lisa, Hillen, Uwe, Gutzmer, Ralf, Goldinger, Simone M., Ugurel, Selma, Gogas, Helen J., Egberts, Friederike, Berking, Carola, Trefzer, Uwe, Loquai, Carmen, Weide, Benjamin, Hassel, Jessica C., Gabriel, Stacey B., Carter, Scott L. ... Schadendorf, Dirk (2014). The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 4 (1), 94-109. doi: 10.1158/2159-8290.CD-13-0617
2014
Journal Article
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
Goldinger, Simone M., Zimmer, Lisa, Schulz, Carsten, Ugurel, Selma, Hoeller, Christoph, Kaehler, Katharina C., Schadendorf, Dirk, Hassel, Jessica C., Becker, Juergen, Hauschild, Axel and Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50 (2), 406-410. doi: 10.1016/j.ejca.2013.09.014
2013
Conference Publication
Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanoma
Schilling, B., Suttorp, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kaehler, K., Utikal, J., Gutzmer, R., Al Ghazal, P., Goldinger, S., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2013). Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanoma. HOBOKEN: WILEY-BLACKWELL.
2013
Conference Publication
Registry for advanced melanoma in Switzerland
Mangana, J., Frauchiger, A., Goldinger, S. M., Gautschi, M., Von Moos, R., Romano, E., Michielin, O., Levesque, M. P. and Dummer, R. (2013). Registry for advanced melanoma in Switzerland. HOBOKEN: WILEY-BLACKWELL.
2013
Conference Publication
Hyponatraemia and Tachyarrhythmia During Ipilimumab: Lessons from the Autopsy
Murer, C., Goldinger, S. M., Maggio, Marques E., Bjasch, D., Stieger, P., Mihic-Probst, D., Schad, K. and Dummer, R. (2013). Hyponatraemia and Tachyarrhythmia During Ipilimumab: Lessons from the Autopsy. HOBOKEN: WILEY-BLACKWELL.
2013
Conference Publication
Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
Goldinger, Simone M., Murer, Carla, Stieger, Pascale and Dummer, Reinhard (2013). Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2013
Conference Publication
The genetic landscape of clinical resistance to RAF inhibition in melanoma
Van Allen, Eliezer Mendel, Wagle, Nikhil, Carter, Scott L., Sucker, Antje, Farlow, Deborah Norman, Hodis, Fran, Taylor-Weiner, Amara, Berking, Carola, Egberts, Friederike, Hassel, Jessica Cecile, Gogas, Helen, Gutzmer, Ralf, Goldinger, Simone M., Loquai, Carmen, Ugurel, Selma, Zimmer, Lisa, Gabriel, Stacey B., Getz, Gad, Garraway, Levi A. and Schadendorf, Dirk (2013). The genetic landscape of clinical resistance to RAF inhibition in melanoma. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2013
Conference Publication
Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?
Mangana, Joanna, Goldinger, Simone M., Schindler, Katja, Rozati, Sima, Frauchiger, Anna L., Rechsteiner, Markus, Moch, Holger, Romano, Emanuela, Kaehler, Katharina C., Michielin, Olivier, Hauschild, Axel, Hoeller, Christoph and Dummer, Reinhard (2013). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2013
Conference Publication
The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
Heinzerling, L., Goldinger, S. M., Voskens, C. J., Loquai, C., Robert, C., Berking, C., Eigentler, T., Fluck, M., Garbe, C., Gutzmer, R., Gleiss, H., Hauschild, A., Hein, R., Justich, A., Keller, U., Klein, C., Mateus, C., Mohr, P., Paetzold, S., Satzger, , Schadendorf, D., Schlaeppi, M., Ulrich, J., Vaubel, J., von Moos, R., Weder, P., Wilhelm, T., Kaehler, K., Goeppner, D. ... Schuler, G. (2013). The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. HOBOKEN: WILEY-BLACKWELL.
2013
Journal Article
RASopathic Skin Eruptions during Vemurafenib Therapy
Rinderknecht, Jeannine D., Goldinger, Simone M., Rozati, Sima, Kamarashev, Jivko, Kerl, Katrin, French, Lars E., Dummer, Reinhard and Belloni, Benedetta (2013). RASopathic Skin Eruptions during Vemurafenib Therapy. Plos One, 8 (3) e58721. doi: 10.1371/journal.pone.0058721
2013
Journal Article
Melanoma immunotherapy: historical precedents, recent successes and future prospects
Raaijmakers, Marieke I. G., Rozati, Sima, Goldinger, Simone M., Widmer, Daniel S., Dummer, Reinhard and Levesque, Mitchell P. (2013). Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy, 5 (2), 169-182. doi: 10.2217/IMT.12.162
2013
Journal Article
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens, Caroline J., Goldinger, Simone M., Loquai, Carmen, Robert, Caroline, Kaehler, Katharina C., Berking, Carola, Bergmann, Tanja, Bockmeyer, Clemens L., Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Gutzmer, Ralf, Grabbe, Stephan, Hauschild, Axel, Hein, Ruediger, Hundorfean, Gheorghe, Justich, Armin, Keller, Ullrich, Klein, Christina, Mateus, Christine, Mohr, Peter, Paetzold, Sylvie, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens ... Heinzerling, Lucie M. (2013). The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. Plos One, 8 (1) e53745. doi: 10.1371/journal.pone.0053745
2012
Journal Article
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8<SUP>+</SUP> T-cell responses in melanoma patients
Goldinger, Simone M., Dummer, Reinhard, Baumgaertner, Petra, Mihic-Probst, Daniela, Schwarz, Katrin, Hammann-Haenni, Anya, Willers, Joerg, Geldhof, Christine, Prior, John O., Kuendig, Thomas M., Michielin, Olivier, Bachmann, Martin F. and Speiser, Daniel E. (2012). Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients. European Journal of Immunology, 42 (11), 3049-3061. doi: 10.1002/eji.201142361
2012
Journal Article
From chemotherapy to targeted treatment
Dummer, R., Rozati, S., Eggmann, N., Rinderknecht, J. and Goldinger, S. M. (2012). From chemotherapy to targeted treatment. Annals of Oncology, 23, 101-103. doi: 10.1093/annonc/mds308
Supervision
Availability
- Associate Professor Simone M Goldinger is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Media
Enquiries
For media enquiries about Associate Professor Simone M Goldinger's areas of expertise, story ideas and help finding experts, contact our Media team: